Press Releases

AMA applauds FDA for approving naloxone product to prevent overdoses

| 2 Min Read

“The American Medical Association (AMA) applauds the Food and Drug Administration (FDA) for approving the nasal spray version of naloxone, a life-saving medication that can reverse the effects of an opioid overdose by restoring breathing and preventing death. The FDA’s swift action will widely increase accessibility to this medication that will help prevent more opioid-related overdoses and save more lives.

“The AMA has long advocated in support of a multi-pronged approach to addressing prescription drug abuse and diversion, which includes increasing access to naloxone for patients who need it.

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Speech balloons

Physicians must tell their own story—for patients’ sake

| 3 Min Read
Profiles positioned as data points across a map of the U.S.

What tops the state advocacy agenda for doctors in 2026

| 7 Min Read
Supportive group holding hands

Time for decisive action on substance-use disorder treatment

| 5 Min Read
Sitting health care worker in a busy hallway

1 in 3 NPs and PAs switch specialties at least once in career

| 6 Min Read